Why the study?
To further study the neutralizing capacity of investigational sIPV immune serum against Sabin, Salk, and recently circulating poliovirus strains.
Does Sabin strain inactivated poliovirus vaccine (sIPV) generate neutralizing capacity against multiple poliovirus strains in infants?
Does Sabin strain inactivated poliovirus vaccine (sIPV) generate neutralizing capacity against multiple poliovirus strains in infants?
Answers are grounded in this paper and cite their sources.
sIPV generates good immunogenicity against multiple poliovirus strains, offering an affordable and practical option for polio eradication.
Introduction: Sabin strain inactivated poliovirus vaccine (sIPV) developed by Sinovac Biotech Co., Ltd., has shown good safety and immunogenicity against parental strains among infants in several finished pre-licensure clinical trials.Areas covered: To further study the neutralizing capacity of investigational sIPV immune serum against Sabin, Salk and recently circulating poliovirus strains, neutralization assay against ten individual strains was performed on backup serum collected from 250 infant participants of the finished phase II clinical trial.Expert commentary:: The sIPV can generate good immunogenicity against Sabin, Salk and recently circulating poliovirus strains. Taking into account its lower containment requirements and financial costs compared with the conventional Salk strain inactivated poliovirus vaccine, sIPV is an affordable and practical option for polio eradication.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: